FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for gabapentin from BluePoint Laboratories, granting approval of a generic version under ANDA077662.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Seizures
• Postherpetic Neuralgia

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

SUPPL AP for GABAPENTIN (GABAPENTIN)